0001209191-18-002050.txt : 20180104
0001209191-18-002050.hdr.sgml : 20180104
20180104170923
ACCESSION NUMBER: 0001209191-18-002050
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180102
FILED AS OF DATE: 20180104
DATE AS OF CHANGE: 20180104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Birznieks Gunther
CENTRAL INDEX KEY: 0001702031
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34186
FILM NUMBER: 18510951
MAIL ADDRESS:
STREET 1: 2200 PENNSYLVANIA AVE NW
STREET 2: SUITE 300E
CITY: WASHINGTON
STATE: DC
ZIP: 20037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vanda Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001347178
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 030491827
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2200 PENNSYLVANIA AVE NW
STREET 2: SUITE 300E
CITY: WASHINGTON
STATE: DC
ZIP: 20037
BUSINESS PHONE: 202-734-3400
MAIL ADDRESS:
STREET 1: 2200 PENNSYLVANIA AVE NW
STREET 2: SUITE 300E
CITY: WASHINGTON
STATE: DC
ZIP: 20037
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-01-02
0
0001347178
Vanda Pharmaceuticals Inc.
VNDA
0001702031
Birznieks Gunther
2200 PENNSYLVANIA AVE NW, SUITE 300E
WASHINGTON
DC
20037
0
1
0
0
SVP, Business Development
Common Stock
2018-01-02
4
S
0
8568
15.2634
D
118366
D
Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs as reflected in this Form 4. Such sale was executed pursuant to an irrevocable election made by the Reporting Person during an open trading window under a program approved by the Compensation Committee of the Issuer's Board of Directors.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.25 to $15.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
/s/ Gunther Birznieks
2018-01-04